Gilead will lay off 114 people: The development of Trodelvy will change?
- Engineered Soybeans with Pig Protein: A Promising Alternative or Pandora’s Dish?
- Severe Fever with Thrombocytopenia Syndrome (SFTS): A Tick-Borne Threat with High Mortality
- Why Isolating Bananas Extends Their Shelf Life?
- This common vitamin benefits the brain and prevents cognitive decline
- New report reveals Nestlé adding sugar to infant formula sold in poor countries
- Did Cloud Seeding Unleash a Deluge in Dubai?
Gilead will lay off 114 people: The development of Trodelvy will change?
- Red Yeast Rice Scare Grips Japan: Over 114 Hospitalized and 5 Deaths
- Long COVID Brain Fog: Blood-Brain Barrier Damage and Persistent Inflammation
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
Gilead will lay off 114 people: The development of Trodelvy will change?
Recently, Gilead submitted a layoff notice to the New Jersey Worker Adjustment and Retraining Notification (WARN), which will lay off 114 employees in Morris Plains, New Jersey. The layoffs will be carried out in three batches in April, September and December.
The news came as a surprise, as the company just said in early March that the Trodelvy-02 Phase III clinical trial had reached its primary endpoint, achieving a 30% reduction in the risk of disease progression or death in patients with HR+/HER2 metastatic breast cancer.
Morris Plains, the former headquarters of Immunomedics after Gilead bought Immunomedics and its breast cancer drug Trodelvy for $21 billion in 2020, rose more than 105% in premarket trading.
This acquisition is a major move for Gilead to leave the field of hepatitis treatment and enter the field of oncology, which has not made much achievements in the field of hepatitis before. Therefore, Trodelvy is expected to become the cornerstone of the company’s oncology research.
At that time, Trodelvy had been shown to have a significant improvement in overall survival and progression-free survival in patients with advanced metastatic triple-negative breast cancer (mTNBC), and the independent data safety monitoring committee also recommended that the phase III ASCENT trial of Trodelvy could be completed as soon as possible. bodes well for progress.
However, the poor response to the market results so far seems to have forced Gilead to make this layoff move, but the company has yet to issue an official statement on its layoff plans, whether the layoffs involve Gilead employees, or a mix with Morris Plains, and The relevant positions are still unknown.
In an interview with reporters, a Gilead spokesman said they were relocating from the Morris Plains factory to a larger factory near the same area, but the new factory would serve as the company’s offices and talent center and would no longer house any manufacturing jobs to strengthen the company’s presence in the area. development of the East Coast region.
Compared with the layoff plan, Trodelvy’s clinical research is still progressing in an orderly manner. Gilead Chief Medical Officer Merdad Parsey, MD, said in a press release that the company is accelerating the approval of Trodelvy for HR+/HER2- metastatic breast cancer, as well as expanding the indication for metastatic bladder cancer, and is conducting trials across multiple tumor types and A study of early treatment lines.
Reference：
Gilead Braces For 114 Job Cuts at Former Immunomedics Facility
Gilead will lay off 114 people: The development of Trodelvy will change?
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
